Tekla Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Tekla Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-529,226	Closed	-$5.13M	–	202
2021 Q2	$5.13M	Hold	529,226	–	–	0.17%	117
2021 Q1	$5.68M	Sell	529,226 -288,558	-35%	-$3.57M	0.2%	108
2020 Q4	$12M	Buy	817,784 +369,735	+83%	+$5.33M	0.42%	69
2020 Q3	$6.37M	Hold	448,049	–	–	0.24%	94
2020 Q2	$3.63M	Hold	448,049	–	–	0.14%	125
2020 Q1	$1.81M	Buy	448,049 +1,950	+0.4%	+$7.37K	0.08%	140
2019 Q4	$459K	Hold	446,099	–	–	0.02%	197
2019 Q3	$137K	Hold	446,099	–	–	0.01%	186
2019 Q2	$146K	Hold	446,099	–	–	0.01%	194
2019 Q1	$294K	Hold	446,099	–	–	0.01%	188
2018 Q4	$763K	Sell	446,099 -22,300	-5%	-$66.9K	0.03%	174
2018 Q3	$2.72M	Hold	468,399	–	–	0.1%	128
2018 Q2	$2.81M	Hold	468,399	–	–	0.11%	120
2018 Q1	$3.37M	Buy	468,399 +18,399	+4%	+$140K	0.13%	109
2017 Q4	$3.29M	Sell	450,000 -50,000	-10%	-$414K	0.13%	105
2017 Q3	$2.58M	Hold	500,000	–	–	0.09%	108
2017 Q2	$1.98M	Buy	+500,000	New	+$2.77M	0.07%	112
2015 Q4	–	Sell	-65,000	Closed	-$847K	–	159
2015 Q3	$847K	Hold	65,000	–	–	0.03%	153
2015 Q2	$1.42M	Buy	+65,000	New	+$1.48M	0.05%	102

Other funds holding TRIL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

OPU

Omni Partners US Irvine, California $1.95B AUM

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Tekla Capital Management's TRIL Position: Q3 2021 in Review

Tekla Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 529,226 shares — an estimated $5.13M sold.

Tekla Capital Management first reported a position in TRIL in Q2 2015 and held it in 19 quarters. The position peaked at $12M in Q4 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

Tekla Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
Tekla Capital Management sold 529,226 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $5.13M.
Tekla Capital Management first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 19 quarters.
Tekla Capital Management's Trillium Therapeutics Inc. position peaked at $12M in Q4 2020.
181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.